Special Issue

Metal Based Drugs: Opportunities and Challenges

Message from the Guest Editors

Metal-based drugs are used for a wide range of human diseases, beyond their well-known applications in cancer (cisplatin) or rheumatoid arthritis (auranofin). The development of drugs based on coordination compounds, *i.e.*, metal complexes, offers the possibility of great structural versatility, compared to purely organic molecules, as they are generated from the combination of different metal ion(s) with distinct ligand(s). The binding of the ligand to the metal ion gives rise to drastic changes in the biological properties of both the organic (ligand) and the inorganic (metal) part. Metal complexes may exert their therapeutic effect through the interaction with cellular organelles, inhibition of enzymes, alteration of the cell membrane, enhanced lipophilicity, cell–cycle arrest, *etc*. This Special Issue is aimed at providing a forum for the dissemination of information on the most recent and relevant research in this topical and exciting area of current investigation.
Dr. Ana Belén Caballero

Guest Editors

Prof. Dr. Patrick Gamez
ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain

Dr. Ana B. Caballero
nanoBIC, Departament de Química Inorgànica i Orgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1–11, 08028 Barcelona, Spain

Deadline for manuscript submissions

closed (10 July 2017)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/7060

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).